Does AstraZeneca CEO Pascal Soriot really want to merge with Gilead? A Bloomberg story suggests he was interested — but it's hard to see why
Pascal Soriot has evidently been thinking big.
Completely out of left field, Bloomberg today posted a story early Sunday saying that AstraZeneca execs have approached Gilead to see if the big biotech would be interested in joining up in a historic biopharma merger. No numbers have been mentioned yet, and no decisions have been made. Right now, according to the business news service, it’s time to check everyone’s temperature.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 142,700+ biopharma pros reading Endpoints daily — and it's free.